# A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

> **NCT06260748** · PHASE3 · WITHDRAWN · sponsor: **Leadiant Biosciences, Inc.**

## Conditions studied

- Cerebrotendinous Xanthomatoses

## Interventions

- **DRUG:** Chenodeoxycholic acid
- **DRUG:** Chenodeoxycholic acid Placebo

## Key facts

- **NCT ID:** NCT06260748
- **Lead sponsor:** Leadiant Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-27
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of feasibility
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06260748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06260748, "A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06260748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*